The neuropeptide oxytocin (OXT) has been revealed as a profound anxiolytic and antistress factor of the brain, besides its many prosocial and reproductive effects. Therefore, there is substantial scientific and medical interest in its potential therapeutic use for the treatment of psychopathologies associated with anxiety, fear, and social dysfunctions, such as generalized anxiety disorder, posttraumatic stress disorder, and social anxiety disorder, as well as autism and schizophrenia, among others. Focusing on preclinical studies, we review the existing evidence for the regulatory capacity of OXT to fine-tune general and social anxiety-related behaviors, as well as cued and social fear conditioning from a translational perspective. The available evidence from animal and human studies substantiates the hypothesis of an imbalance of the endogenous brain OXT system in the etiology of anxiety disorders, particularly those with a social component such as social anxiety disorder. In addition, such an imbalance of the OXT system is also likely to be the consequence of chronic OXT treatment resulting in a dose-dependent reduction in OXT receptor availability and increased anxiety.
Anxiety disorders, such as generalized anxiety disorder (GAD), posttraumatic stress disorder (PTSD), and social anxiety disorder (SAD), are among the most common psychiatric illnesses with a lifetime prevalence of approximately 30% (1) . GAD is defined as a persistent and unnecessary anxiety of everyday life and/or events for a period of at least 6 months. The main treatment options for GAD are benzodiazepines and beta blockers or drugs originally used for major depressive disorder. SAD and PTSD, the second and third most prevalent anxiety disorders, respectively, are largely characterized by fear of a previously encountered situation (2, 3) . PTSD occurs in a subset of people who have witnessed, or experienced, a traumatic event, such as war or personal assault, and is manifest as flashbacks of the event or, in more serious cases, generalization of the event to similar contexts. In contrast, SAD, also often referred to as social phobia, is characterized by the persistent fear and avoidance of social situations (4) . There are two main forms of SAD: specific SAD, which is described as fear and avoidance of particular social situations and interactions (e.g., fear of public speaking) (5) , and generalized SAD, characterized by the avoidance of all social situations (6) (7) (8) . Treatment for PTSD and SAD is rather unspecific and involves cognitive psychotherapy in combination with pharmacotherapies originally designed for depression or GAD.
These anxiety disorders are highly comorbid with other affective disorders, including major depressive disorder, autism, or Prader-Willi-syndrome (9, 10) . Interestingly, symptoms of SAD often emerge first, indicating that SAD may be a major risk factor for other psychiatric disorders. Therefore, early specific intervention of social fear might reduce the risk of comorbidities. However, treatment of anxiety disorders generally achieves only partial remission of symptoms or shows a high rate of relapse (11) , highlighting the necessity for more specific treatment options. Recently, neuropeptides have emerged as viable candidates, such as oxytocin (OXT), arginine vasopressin (AVP) (12) [for reviews, see (13, 14) ], neuropeptide Y (15) , and neuropeptide S (16) (17) (18) .
BRIEF OVERVIEW OF THE BRAIN OXT SYSTEM AS A POTENTIAL THERAPEUTIC TARGET
The first reported behavioral effects of the two closely related neurohypophysial nonapeptides OXT and AVP date back to the 1960s and 1970s, when effects on maternal behavior (19) and on memory functions (20) , respectively, were described. From a translational view, AVP first predominated scientific interest due to its anxiogenic and depressive-like effects [for review, see (13, 21) ]. However, despite the development of various nonpeptidergic AVP receptor antagonists, research in this direction has almost halted due to a lack of clinical efficacy. In contrast, the discovery of anxiolytic, antistress, and prosocial effects of OXT in rodents in the 1990s has promoted a switch to this nonapeptide. This has further been facilitated by the discovery of a plethora of OXT effects after intranasal application in humans [see below and (22, 23) ]. The physiology of the hypothalamic-neurohypophysial system and its main neuropeptides OXT and AVP has become a textbook example. Briefly, the synthesis of OXT and AVP in magnocellular neurons located within the supraoptic (SON), paraventricular (PVN), and accessory nuclei of the hypothalamus (24) ; the electrophysiological properties of such neurons; stimuli triggering their peripheral secretion into blood; and subsequent physiological functions are well defined. Moreover, although our knowledge regarding other sites of neuronal synthesis, neuropeptidergic circuitries (25, 26) and region-and stimulus-dependent central release patterns (14, 26, 27 ) is continuously rising, many aspects are still a matter of intense research interest. For example, the subcellular location of OXT receptors (OXT-R) at either axosynaptic, dendritic or somatic fractions; the dynamics of local receptor expression and binding; and associated intracellular signaling cascades that determine-possibly sex-dependent-OXT actions are largely unknown (28, 29) . Such details are essentially needed before OXT can be considered a routine treatment option for anxietyrelated diseases or social dysfunctions.
OXT INVOLVEMENT IN ANXIETY-RELATED BEHAVIOR

Responsiveness of the OXT System to Anxiety and Stress
Anxiogenic and stressful stimuli significantly activate the body's OXT system, as reflected by increased electrophysiological activity of OXT neurons, increased OXT gene expression within the SON and PVN, and stimulated peripheral and intracerebral OXT release (30) (31) (32) (33) (34) (35) [for review, see (14, 27, 36) ]. For example, exposure of male rats to novelty, forced swimming, or social defeat rapidly increases OXT release into blood but also within the PVN and/or SON and in other limbic brain regions, such as the central amygdala or septum (27, 36) . Similarly, increased OXT release into blood (37) and within the PVN and central amygdala (38) has also been found in female rats exposed to psychosocial stress (maternal defeat by an aggressive lactating resident dam). Magnocellular OXT neurons within the PVN (or SON) themselves may provide the neuroanatomical basis for these observations: in addition to their projections to the neurohypophysis, they can also release OXT locally within the PVN (or SON) from dendrites and perikarya, as well as from axon collaterals that project to distinct brain regions, for example, the central amygdala (39, 40) . Thus, it is tempting to conclude that fearful and stressful events activate the OXT system and, consequently, both peripheral and central OXT release (27, 36) [but see (41) ]. This is an important observation with implications for human studies, as it speaks in favor of peripheral OXT measures being a global biomarker for the general activity of the endogenous OXT system also, at least partly, reflecting the central (re)activity of an individual's OXT system to stress. However, we have to be aware of the fact that plasma OXT may, at best, only roughly reflect the temporal dynamics of central release patterns, which was shown to substantially differ from peripheral release patterns of OXT (14, 27, (41) (42) (43) . Further, plasma OXT necessarily ignores brain region-dependent events, which play an important role in the behavioral effects of OXT (see below).
Whereas these OXT-related events are well-characterized in rodents, there are only a few human reports of stress-or anxiety-induced changes in plasma OXT, such as in response to physical exercise (running), psychosocial stress (e.g., separation), or fear (44) (45) (46) (47) . This is surprising given that plasma (or saliva) OXT is the only easily accessible biomarker of the human OXT system. However, reliable assays are an important prerequisite [for details, see (48, 49) and Leng and Ludwig (50) , this issue]. In several published studies, the validity of OXT data obtained with enzyme-linked immunosorbent assay from plasma samples without prior extraction procedure is questionable; corresponding studies are, therefore, not listed here.
Acute Anxiolytic Effects of OXT
Once released within the brain, OXT acts as a key modulator of anxiety-related behaviors and hypothalamic-pituitaryadrenal axis activity (51, 52) . Relatively simple pharmacologic approaches using intracerebroventricular (icv) or local (PVN, central amygdala, prefrontal cortex) administration of an OXT-R agonist or antagonist have consistently shown an anxiolytic effect of synthetic or endogenous OXT in male and female rodents (53) (54) (55) (56) (57) (58) . Particularly intriguing is the anxiolytic effect of endogenous brain OXT during periods of robust activation and increased central release, including lactation (51, 57, 59 ) and sexual activity in both male and female rodents (60) (61) (62) . In contrast, under nonreproductive and stress-free conditions (and thus low OXT system activity), we have never been able to reveal an anxiolytic effect of brain OXT using an OXT-R antagonist. Thus, endogenous OXT does not seem to play a major role in the maintenance of a basal level of anxiety, but rather comes into play during psychosocial or physiological activation of the system. Behavioral data from transgenic mice lacking OXT provide further support for the anxiolytic importance of brain OXT in anxiety regulation, as female knockout mice show greater anxiety-related behavior than their wildtype counterparts on the elevated plus maze (63) (for a summary of these findings including doses and tests employed, please see Table 1) .
We have also shown that the robust anxiolytic activity of OXT in the PVN depends on the sequential activation of several OXT-R-mediated intraneuronal signaling pathways. Specifically, local infusion of OXT results in activation of the mitogen-activated protein kinase pathway (54, 57) , and blockade of this pathway prevents the local anxiolytic effects of OXT. Interestingly, in the peripartum period, both the OXT system and the OXT-R-driven mitogen-activated protein kinase pathway are highly activated within the PVN, even in the absence of synthetic OXT (57) . Blockade of the signaling pathway also prevents the anxiolytic state of lactating rats. Additionally, we could recently identify that increased intracellular calcium levels via insertion of transient receptor potential vanilloid (TRPV) channels into the membrane also mediates the acute anxiolytic effect of OXT in the PVN (64) . interest. However, relevant basic studies are rare, and those performed reveal that chronic OXT effects strongly depend on the dose and duration of application, are likely to vary between male and female subjects (65) (66) (67) (68) (69) (70) (71) (72) , and are dependent upon the innate level of anxiety (65) . For example, in male mice, chronic icv infusion of OXT (10 ng/hour) over 2 weeks induced a robust increase in anxiety-related behavior in two independent behavioral tests, whereas a tenfold lower dose did not alter anxiety (67) . In contrast, in ovariectomized, steroid-treated female rats, 5 days of icv OXT (10 ng/hour) reduced anxiety levels and stress-induced c-Fos activation in relevant brain regions (66, 72) . In support of such sex differences, 7 days icv OXT (20 ng/hour) in male rats did not affect anxiety-related behavior (69) .
Chronic Effects of Synthetic OXT on Anxiety
To further test for the potential therapeutic value of OXT in the context of anxiety disorders, we proved its efficacy in rats selectively bred for high anxiety-related behavior (HAB) versus low anxiety-related behavior (LAB) (13, 73) . Interestingly, we only found an anxiolytic effect of OXT in female, but not male, HAB rats after chronic, but not acute, icv application. In contrast, LAB females administered chronic OXT-R antagonist showed increased anxiety-related behavior, which provides further indication for a role of the endogenous OXT system in the anxiety phenotype of HAB and LAB female rats (65) . The relatively low effectiveness of OXT to modulate extreme anxiety levels in these animals is likely due to their rigid genetic predisposition toward the selected behavioral trait, namely anxiety.
Importantly, chronic icv infusion as well as repeated (twice daily) nasal application of synthetic OXT were found to affect the endogenous OXT system by reducing OXT-R binding in several brain regions relevant for anxiety regulation (septum, amygdala, median raphe nucleus, nucleus accumbens, hippocampus) (67, 68) . These findings follow a general principle in neuropharmacology in that persistent agonist stimulation by chronic exposure to the receptor ligand, OXT in this case, results in downregulation and desensitization of receptors (74) . Interestingly, after chronic OXT treatment, AVP receptor binding was found to be increased in the lateral septum (68) , where AVP exerts robust anxiogenic effects (12) . In this context, it is worth mentioning that OXT can bind to AVP receptors (and vice versa) (75) , but to what extent chronic alterations in OXT or OXT-R availability directly affect AVP receptor expression remains unknown at present.
Taken together, these studies highlight potential species and sex differences in the response to chronic OXT (for summary see Table 1 ). Without any doubt, we have to expect similar undesired counterregulatory consequences after chronic or repeated intranasal OXT application in humans, and more detailed basic studies are essentially needed.
OXT AND GENERAL ANXIETY: HUMAN RESEARCH
Human researchers have suggested a possible relationship between peripheral OXT levels, OXT-R gene polymorphisms, and GAD. In detail, basal plasma OXT concentrations were found to depend upon the mental health state and gender of the test person. For example, a positive relationship between (basal) plasma OXT and state anxiety has been reported in women (47,76), whereas plasma (and cerebrospinal fluid) OXT concentrations negatively predicted trait anxiety scores in a mixed-gender cohort (11 male and 16 female subjects) of child and adult patients (46) and in male, but not female, subjects in another study (77) . Moreover, associations between OXT-R polymorphisms and anxiety were described with two single nucleotide polymorphisms (SNPs), rs53576 and rs2254298, found to be associated with separation anxiety in depressed patients (78) and to interact with the level of anxiety symptoms in adolescent girls (79) . Similarly, in a large study assessing multiple OXT-R polymorphisms, an interaction between retrospectively assessed early-life stress exposure and OXT-R genotype on self-reported anxiety symptoms was found (80) . However, the functional implications of these SNPs on the OXT system remain to be shown.
There have been surprisingly few attempts to investigate whether intranasal OXT has anxiolytic properties in GAD patients (81) [see (22) for review]. This one study supports a beneficial effect of daily OXT administration in GAD patients over 3 weeks, especially in male subjects (80) . In the context of human anxiety, the majority of studies have been performed in volunteers in variants of the Trier Social Stress Test, which, on the whole, revealed that acute intranasal OXT reduces anxiety symptoms (82) (83) (84) (85) (86) . However, it is clear that further studies assessing the effect of chronic or repeated OXT administration, and in GAD patients, are warranted.
THE BALANCED ACTIVITY OF THE BRAIN OXT SYSTEM IN GENERAL ANXIETY REGULATION
Regarding the role of OXT in animal and human anxiety regulation, we have previously hypothesized that the balanced activity of brain OXT (and AVP) systems importantly impacts on emotional (and social) behaviors along a continuum reaching from mental health up to psychopathology (21) (Figure 1 ). For example, low brain OXT activity, hypothesized to be associated with high anxiety levels, can be reflected by 1) low hypothalamic OXT gene expression, 2) low levels of central OXT release and OXT availability in the local extracellular fluid under basal and/or stimulated conditions, and/or 3) low OXT-R expression and binding in brain regions relevant for emotional and social behaviors. These parameters can be shifted towards the right (Figure 1 ) by physiological (e.g., lactation, sexual activity) and environmental (e.g., positive social interactions) stimuli and are likely determined by genetic and epigenetic factors. Moreover, increasing the availability of OXT in the brain extracellular fluid, possibly in combination with psychopharmacotherapy, may also result in a shift of OXT activity toward the right (Figure 1) . Indeed, factors that acutely increase the activity of the OXT system have been shown to reduce state anxiety and to promote prosocial behaviors (see below). However, an adaptive shift of the brain OXT system toward the left, for example, in chronic adverse life environments, might be important to ensure evolutionary beneficial anxiety levels.
OXT AND CUED FEAR CONDITIONING AS A RODENT MODEL OF POSTTRAUMATIC STRESS DISORDER
Inability to extinguish fear memories is a core symptom in several psychiatric disorders, such as PTSD, SAD, and panic disorder, and has been linked to hyperactivity of the amygdala (87, 88) . Cued fear conditioning has been used in laboratory animals as a model of PTSD and involves pairing a neutral stimulus (tone or light as conditioned stimulus) with an aversive, unconditioned stimulus, such as a mild foot shock, thereby eliciting a freezing response to the previously neutral stimulus (89, 90) . During fear extinction performed 24 hours later and repeated exposure to the conditioned stimulus only, the conditioned response should be attenuated via processes of relearning (91, 92) .
Initial studies revealing distinct and differential c-Fos activation of OXT neurons following various phases of fear conditioning supported a role for the endogenous OXT system in fear acquisition and extinction (93) . Thereafter, studies revealed that, as with other systems that affect fear learning, the timing and location of OXT administration critically determine its outcome. Thus, we could demonstrate in male rats that icv OXT before acquisition of cued fear conditioning did not affect cued fear acquisition, as OXT-infused rats learned the association between the conditioned and unconditioned stimulus to the same degree as control rats. In contrast, the same treatment decreased fear expression 24 hours later. In confirmation of a substantial role of brain OXT in fear consolidation, icv administration of an OXT-R antagonist at the same time impaired fear extinction. Surprisingly, when applied 10 minutes before fear extinction training, icv OXT impaired, whereas the OXT-R antagonist facilitated, cued fear extinction (94) . Moreover, the effects of OXT on fear expression and extinction appear to be region specific. Infusion of OXT into the basolateral amygdala of male rats before contextual fear conditioning led to enhanced fear expression and impaired extinction, whereas infusion of either WAY-267464 or TGOT (both OXT agonists) into the central amygdala before fear conditioning reduced fear expression (95) . In an elegant study, optogenetically stimulated local release of OXT as well as synthetic OXT infusion in the central amygdala of rats before contextual fear extinction reduced fear expression by reducing the output of the centromedial amygdala in response to the conditioned stimulus (39, 96, 97) .
Taken together, these studies support a role of the endogenous OXT system in the acquisition and extinction of fear, and this appears to be time-and region-dependent (for summary see Table 1 ). Moreover, these temporally-and spatially-dependent effects of OXT on fear extinction clearly extend our model of the balanced brain OXT system (Figure 1 ) and indicate an adaptive role of OXT in fear conditioning. A generally high OXT activity at the time of acquisition, due to either endogenous factors or pharmacologic manipulation, is likely to be associated with lower fear expression. However, once cued fear has consolidated, an acute high OXT may rather impair fear extinction.
Also, these findings have to be carefully considered and extended before using OXT for the treatment of PTSD caused by nonsocial traumatic events. However, as we will see further in the text, OXT seems to be particularly effective only in a social context.
OXT EFFECTS ON SOCIAL BEHAVIOR: FROM SOCIAL PREFERENCE TO SOCIAL FEAR
The prosocial effects of OXT are extensively summarized elsewhere (23, 85, (98) (99) (100) , but in this context, it is worth mentioning that brain OXT is essential for naturally occurring social preference behavior in rats and mice as analyzed in the social preference-avoidance test (4, 101) . In detail, OXT was found to be released within the lateral septum during social interaction and investigation of conspecifics (102) . Blockade of central receptor-mediated OXT actions by icv infusion of an OXT-R antagonist prevented social preference behavior in rodents (101) . Moreover, exposure to 30 minutes of social defeat by a slightly larger male resident rat before the social preference test induced an avoidance of the conspecific, which could be acutely reversed by icv infusion of OXT. These observations together with the findings that OXT knockout mice display impaired social behaviors (103) support the hypothesis that high levels of brain OXT activity generally promote naturally-occurring social preference and social competence (Figure 1 ). Although further, and especially more longlasting, studies are needed, the possibility emerged of OXT being a treatment option for social dysfunctions and, specifically, for social fear (101) .
However, social defeat can result in a variety of other symptoms that may influence social anxiety. Therefore, to more specifically study the role of OXT in social fear, we have recently established an operant social fear conditioning paradigm in mice, where conditioned mice receive a footshock when actively investigating a conspecific (4, 104, 105) . As a result, social fear conditioning specifically induces social fear toward unknown conspecifics, which is expressed as decreased social investigation and aversive responses toward conspecifics in the experimental animal's home cage. Moreover, as occurs in SAD (and PTSD), this fear sensitizes over time and lasts for at least 2 weeks. During fear extinction training, repeated exposure to social stimuli without punishment gradually reinstates social preference behavior, i.e., loss of social fear (4, 104, 105) .
BRAIN OXYTOCIN
Anxiety
Social fear could be associated with profound changes in the brain OXT system, as it specifically resulted in elevated OXT-R binding in regions associated with the fear circuitry, including the dorsolateral septum, central amygdala, hippocampus, and the median raphe nucleus (102) . The alterations in OXT-R binding were found to be reversed after social fear extinction. In support of our findings of elevated OXT-R binding in socially fearful mice are the observations that 1) OXT-R expression is locally elevated in chronically defeated mice, which also showed signs of social avoidance (106); and 2) virus-induced overexpression of the OXT-R within the septum increased contextual fear expression (107) . It is likely that these observed changes in OXT-R binding are directly due to reduced local OXT release and availability, as OXT release within the dorsolateral septum during exploration of a conspecific-strongly increased in unconditioned mice-was indeed blunted in social fear conditioning mice. In support, both icv and intraseptal OXT infusion before extinction training abolished fear expression (102) . The findings that OXT strongly facilitates extinction of social fear, in contrast to the differential effects on cued fear extinction, suggest that either the circuitry involved in social fear differs from that of cued fear (see above) or that the combined prosocial and anxiolytic properties of OXT are sufficient to overcome social fear. Thus, increasing brain OXT activity toward the right, for example, by intracerebral infusion of synthetic OXT, and consequently increasing OXT availability in the local extracellular fluid (Figure 1) is associated with the attenuation or even reversal of social fear. To what extent stimulation of the endogenous OXT system may also be beneficial in this context needs to be shown.
OXT IN PTSD AND SOCIAL ANXIETY DISORDER: HUMAN RESEARCH
Numerous human studies have reported on the OXT system in relation to both PTSD and SAD. In one of the first reports assessing intranasal OXT in Vietnam veterans with PTSD, no beneficial effects on physiological responses to combat imagery were observed (108) . However, more recent studies support a beneficial role for intranasal OXT in healthy volunteers exposed to a conditioning/extinction paradigm with respect to the bodily response and reduction of amygdala activity throughout extinction (109, 110) . In contrast, intranasal OXT increased the startle response to unpredictable shocks (111) . Thus, in addition to the temporal and spatial differences of OXT on fear extinction reported above, the nature of the threat (social vs. nonsocial, predictable vs. unpredictable traumatic events) also appears to play an important role in the effectiveness of synthetic OXT in humans.
Various studies performed in SAD patients have assessed plasma OXT levels, OXT-R gene methylation and SNPs, and the effect of intranasal OXT on SAD symptoms. The reports relating to plasma OXT and SAD have been inconsistent and need to be interpreted with caution due, partly, to invalid assay methods (see above). Moreover, reduced OXT-R methylation in SAD patients was associated with symptom severity, elevated stress-induced cortisol responses, and increased amygdala activity (112) . Since decreased methylation is likely to result in increased OXT-R expression, these findings support our results in socially fearful mice (102) . Thus, increased OXT-R expression possibly due to low local OXT release may represent a conserved mechanism whereby the memory of adverse social events is maintained leading to social anxiety.
Intranasal OXT given either alone or in combination with exposure therapy has generally led to positive results in SAD in terms of positive self-evaluation of public performance (113) and regional neuronal activity patterns and amygdala-prefrontal connectivity in response to emotional faces (114) (115) (116) . Also, in fragile X patients, who also display symptoms of social anxiety, intranasal OXT improved eye gazing and reduced cortisol response to a social challenge (117) .
SUMMARY
In summary, there is profound evidence for an important role of the OXT system in general anxiety and social fear, in addition to its many prosocial effects. Differing activities of the brain OXT system, including gene expression patterns and local release, which are determined by genetic and epigenetic factors, are likely to underlie differences in emotional and social behaviors. High central OXT availability, for example, seems to be associated with an anxiolytic and prosocial, socially competent phenotype. In contrast, a gradual shift of the activity scale toward the left, e.g., by diminished OXT-OXT-R interactions, is associated with elevated nonsocial anxiety, lack of social preference, and social fear. However, before the OXT system can be considered a safe treatment target, various molecular, neuronal, and brain network variables need to be studied in more detail after acute, repeated, or chronic OXT application in animal and human studies. Moreover, biological markers of the activity and responsiveness of the endogenous OXT system (Figure 1 ) need to be validated and employed to distinguish potential OXT responders and nonresponders to avoid disadvantageous effects in the latter.
